Sarah B. Goldberg - Publications, H-index & Citations

Sarah B. Goldberg

Yale School of Medicine

48H指数

490论文数

1.3W被引数

收录论文 57

发表时间

NSCLC brain metastases exhibit reduced HLA-I antigen presentation machinery and immune evasion independent of IFNγ signaling defects NSCLC脑转移瘤表现出HLA-I抗原呈递机器减少和免疫逃逸，且与IFNγ信号缺陷无关

Molecular Cancer

IF33.9

2026-05-28

OAAI

Noelia Vilariño; Miguel López de Rodas; Maria Villalba-Esparza; Barani Kumar Rajendran; Boyu Huang; Sara Hijazo-Pechero; Adrien Costantini; Kishu Ranjan; Javier Ramos-Paradas; Benjamin Y. Lu; Ernest Nadal; Sarah B. Goldberg; Don X. Nguyen; Kurt A. Schalper

TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with EGFR -mutated locally advanced or metastatic non-small cell lung cancer TROPION-Lung14研究方案：一项关于奥希替尼联合达托帕姆德鲁克坦与奥希替尼单药作为携带EGFR突变局部晚期或转移性非小细胞肺癌患者一线治疗的III期研究

Therapeutic Advances in Medical Oncology

IF4.2

2026-05-20

PREAI

Shun Lu; Mariano Provencio Pulla; Eldsamira Mascarenhas; Junko Tanizaki; Hye Ryun Kim; Yinglei Liu; Shengmei Feng; Biao Zhang; Laurence Toms; James Chih-Hsin Yang; Sarah B. Goldberg

Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD 奥希替尼联合塞尔鲁替尼在既往一线奥希替尼进展后EGFR突变型晚期NSCLC伴BRAF突变患者中的疗效：ORCHARD研究

European Journal of Cancer

IF7.1

2026-05-18

PREAI

Zofia Piotrowska; Sarah B. Goldberg; Jonathan W. Goldman; Adrianus J. de Langen; Xiuning Le; Isamu Okamoto; Jonathan W. Riess; Helena A. Yu; Kazumi Nishino; Silvia Novello; Santiago Ponce; Helen Ambrose; Paul. E. Smith; Kwan Ho Tang; Jonathan. M. Lehman; Byoung Chul Cho

ERBB2 activating mutations and co-occurring genomic alterations contribute to disease heterogeneity in patients with ERBB2-mutant lung cancer ERBB2激活突变和共发生的基因组改变在ERBB2突变型肺癌患者中贡献于疾病异质性。

Journal of Thoracic Oncology

IF20.8

2026-04-01

PREAI

Paul Stockhammer; Talal El Zarif; Jacob L. Schillo; Fangyong Li; Sarah B. Goldberg; Katerina Politi; Michael J. Grant

Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report 奥希替尼联合萨沃利替尼治疗在一线奥希替尼治疗后具有MET改变的EGFR突变晚期NSCLC患者：临床结局、安全性和生物标志物分析：简要报告

Journal of Thoracic Oncology

IF20.8

2025-10-21

PREAI

Xiuning Le; Christina Baik; Byoung Chul Cho; Jonathan W. Riess; Zofia Piotrowska; Adrianus Johannes de Langen; Sarah B. Goldberg; Jonathan W. Goldman; Noemi Reguart; Yoshimasa Shiraishi; Helen Ambrose; Paula G. Fraenkel; Brayan Merchan Ruiz; Paul E. Smith; Kwan Ho Tang; Helena A. Yu

Intracranial metastases from solid tumors: Call to action and consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology collaborative 颅内转移瘤：神经肿瘤学会和临床肿瘤学会协作的呼吁与共识

Neuro-Oncology

IF13.4

2025-10-06

OAAI

Akanksha Sharma; Lucy Boyce Kennedy; Amanda E D Van Swearingen; Manmeet S Ahluwalia; Stephen J Bagley; Veronica L Chiang; Caroline Chung; Diana M Cittelly; Mariza Daras; Michael A Davies; Peter E Fecci; Daphne A Haas-Kogan; Jona A Hattangadi-Gluth; Katarzyna J Jerzak; Michelle M Kim; Rachna Malani; Minesh P Mehta; Nelson S Moss; Josh Neman; Don X Nguyen; Saul J Priceman; Solmaz Sahebjam; Helen A Shih; Riccardo Soffietti; Nancy Wang; Alexandra Zimmer; Sarah Goldberg; Mustafa Khasraw; Carey K Anders; Nancy U Lin; the SNO/ASCO Brain Metastasis Collaborative Think Tanks; null

Lasering in on Uncommon EGFR Mutations 聚焦罕见EGFR突变

Journal of Thoracic Oncology

IF20.8

2025-09-04

PREAI

So Yeon Kim; Katerina Politi; Sarah B. Goldberg

Comment on Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study Response 关于在不可切除的EGFR突变非小细胞肺癌中，对比巩固治疗奥希替尼与度伐利尤单抗与观察随访的多中心回顾性队列研究：疗效应答

JOURNAL OF THORACIC ONCOLOGY

IF20.8

2025-01-01

PREAI

Nassar, Amin H.; Kim, So Yeon; Adib, Elio; Naqash, Abdul Rafeh; Goldberg, Sarah B.

Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape

CANCER TREATMENT REVIEWS

IF10.5

2024-11-01

OAAI

Weller, Michael; Remon, Jordi; Rieken, Stefan; Vollmuth, Philipp; Ahn, Myung-Ju; Minniti, Giuseppe; Le Rhun, Emilie; Westphal, Manfred; Brastianos, Priscilla K.; Soo, Ross A.; Kirkpatrick, John P.; Goldberg, Sarah B.; Ohrling, Katarina; Hegi-Johnson, Fiona; Hendriks, Lizza E. L.

Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer (vol 24, pg 638, 2018)

NATURE MEDICINE

IF50

2024-08-20

OAAI

Robichaux, Jacqulyne P.; Elamin, Yasir Y.; Tan, Zhi; Carter, Brett W.; Zhang, Shuxing; Liu, Shengwu; Li, Shuai; Chen, Ting; Poteete, Alissa; Estrada-Bernal, Adriana; Le, Anh T.; Truini, Anna; Nilsson, Monique B.; Sun, Huiying; Roarty, Emily; Goldberg, Sarah B.; Brahmer, Julie R.; Altan, Mehmet; Lu, Charles; Papadimitrakopoulou, Vassiliki; Politi, Katerina; Doebele, Robert C.; Wong, Kwok-Kin; Heymach, John V.

PACIFIC-9: Phase III trial of durvalumab plus oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer PACIFIC-9: durvalumab联合oleclumab或monalizumab治疗不可切除的III期非小细胞肺癌的III期试验

FUTURE ONCOLOGY

IF2.6

2024-07-18

OAAI

Barlesi, Fabrice; Cho, Byoung Chul; Goldberg, Sarah B.; Yoh, Kiyotaka; Gelatti, Ana Caroline Zimmer; Mann, Helen; Gopinathan, Aarthi; Bielecka, Zofia Felicja; Newton, Michael; Aggarwal, Charu

EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)-A Podcast Discussion Between Patients and Oncologists EGFR突变并不完全相同: 非小细胞肺癌 (NSCLC) 中生物标志物检测的重要性-患者和肿瘤学家之间的播客讨论

ONCOLOGY AND THERAPY

IF3.2

2023-09-26

OAAI

Liu, Stephen V.; Elkins, Ivy B.; Feldman, Jill; Goldberg, Sarah B.

DASH-HF Study: A Pragmatic Quality Improvement Randomized Implementation Trial for Patients With Heart Failure With Reduced Ejection Fraction

jacc heart failure

IF8.4

2023-09-01

OAAI

Verma, Aradhana; Fonarow, Gregg C.; Hsu, Jeffrey J.; Jackevicius, Cynthia A.; Mody, Freny Vaghaiwalla; Nguyen, Amanda; Amidi, Omid; Goldberg, Sarah; Vetrivel, Reeta; Upparapalli, Deepti; Theodoropoulos, Kleanthis; Gregorio, Stephanie; Chang, Donald S.; Bostrom, Kristina; Althouse, Andrew D.; Ziaeian, Boback

Precise, pragmatic and inclusive: the modern era of oncology clinical trials

NATURE MEDICINE

IF50

2023-07-31

PREAI

Grant, Michael J.; Goldberg, Sarah B.

Management of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy?无遗传驱动改变的非小细胞肺癌脑转移患者的治疗: 前期放疗还是免疫治疗？

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

IF4.2

2023-05-29

OAAI

Merkin, Ross D. D.; Chiang, Veronica L. L.; Goldberg, Sarah B. B.

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC KRASG12C抑制剂在晚期NSCLC中的疗效和作用

CANCER DISCOVERY

IF33.3

2023-04-17

OAAI

Negrao, Marcelo V.; Araujo, Haniel A.; Lamberti, Giuseppe; Cooper, Alissa J.; Akhave, Neal S.; Zhou, Teng; Delasos, Lukas; Hicks, J. Kevin; Aldea, Mihaela; Minuti, Gabriele; Hines, Jacobi; Aredo, Jacqueline V.; Dennis, Michael J.; Chakrabarti, Turja; Scott, Susan C.; Bironzo, Paolo; Scheffler, Matthias; Christopoulos, Petros; Stenzinger, Albrecht; Riess, Jonathan W.; Kim, So Yeon; Goldberg, Sarah B.; Li, Mingjia; Wang, Qi; Qing, Yun; Ni, Ying; Do, Minh Truong; Lee, Richard; Ricciuti, Biagio; Alessi, Joao Victor; Wang, Jing; Resuli, Blerina; Landi, Lorenza; Tseng, Shu-Chi; Nishino, Mizuki; Digumarthy, Subba R.; Rinsurongkawong, Waree; Rinsurongkawong, Vadeerat; Vaporciyan, Ara A.; Blumenschein, George R., Jr.; Zhang, Jianjun; Owen, Dwight H.; Blakely, Collin M.; Mountzios, Giannis; Shu, Catherine A.; Bestvina, Christine M.; Garassino, Marina Chiara; Marrone, Kristen A.; Gray, Jhanelle E.; Patel, Sandip Pravin; Cummings, Amy L.; Wakelee, Heather A.; Wolf, Juergen; Scagliotti, Giorgio Vittorio; Cappuzzo, Federico; Barlesi, Fabrice; Patil, Pradnya D.; Drusbosky, Leylah; Gibbons, Don L.; Meric-Bernstam, Funda; Lee, J. Jack; Heymach, John V.; Hong, David S.; Heist, Rebecca S.; Awad, Mark M.; Skoulidis, Ferdinandos

Molecular determinants of KRAS p.G12C inhibitor efficacy in advanced NSCLC

CANCER RESEARCH

IF16.6

2023-04-04

PREAI

Negrao, Marcelo V.; Araujo, Haniel A.; Lamberti, Giuseppe; Cooper, Alissa J.; Zhou, Teng; Akhave, Neal; Delasos, Lukas; Hicks, J. Kevin; Aldea, Mihaela; Minuti, Gabriele; Hines, Jacobi; Aredo, Jacqueline V.; Dennis, Michael J.; Chakrabarti, Turja; Scott, Susan; Bironzo, Paolo; Scheffler, Matthias; Christopoulos, Petros; Kim, So Yeon; Goldberg, Sarah; Ni, Ying; Resuli, Blerina; Landi, Lorenza; Tseng, Shu-Chi; Nishino, Mizuki; Owen, Dwight; Blakely, Collin; Mountzios, Giannis; Shu, Catherine A.; Bestvina, Christine; Garassino, Marina; Marrone, Kristen; Gray, Jhanelle; Patel, Sandip Pravin; Cummings, Amy L.; Wakelee, Heather A.; Wolf, Jurgen; Scagliotti, Giorgio V.; Cappuzzo, Federico; Barlesi, Fabrice; Patil, Pradnya; Gibbons, Don L.; Meric-Bernstam, Funda; Lee, J. Jack; Heymach, John V.; Hong, David S.; Heist, Rebecca S.; Awad, Mark M.; Skoulidis, Ferdinandos

Tumor immune microenvironment &genomic features of non-small cell lung carcinomas in patients with HIV (PWH)

CANCER RESEARCH

IF16.6

2023-04-04

PREAI

Desai, Shruti; Ranjan, Kishu; Salahuddin, Syim; Yusuf, Ramsey; Gu, Jianlei; Tang, Daiwei; Kong, Yong; Rajendran, Barani Kumar; Zhao, Hongyu; Kluger, Yuval; Goldberg, Sarah; Emu, Brinda; Schalper, Kurt Alex

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy 癌症免疫治疗协会 (SITC) 对免疫检查点抑制剂联合化疗耐药的共识定义

JOURNAL FOR IMMUNOTHERAPY OF CANCER

IF10.6

2023-03-14

OAAI

Rizvi, Naiyer; Ademuyiwa, Foluso O.; Cao, Z. Alexander; Chen, Helen X.; Ferris, Robert L.; Goldberg, Sarah B.; Hellmann, Matthew D.; Mehra, Ranee; Rhee, Ina; Park, Jong Chul; Kluger, Harriet; Tawbi, Hussein; Sullivan, Ryan J.

The end of the beginning: progress and next steps in KRAS-mutant non-small-cell lung cancer

LANCET

IF88.5

2023-03-01

PREAI

Goldberg, Sarah B.; Herbst, Roy S.

研究方向